Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-10-17 DOI:10.1016/j.jhep.2024.10.011

Henry Lik Yuen Chan

引用次数: 0

Abstract

Section snippets

Financial support

none

Declaration of Competing Interest:

HLY Chan is an advisor for Aligos, Glaxo-Smith-Kline, Roche, Vaccitech, Virion Therapeutics; a speaker for Echossens, Gilead, Roche; and a data management board member for Aligos, Arbutus, Precision BioSciences, Roche, Vaccitech, Zhimeng Therapeutics.

查看原文本刊更多论文

将反义寡核苷酸和免疫调节剂的序贯疗法作为治愈 HBV 的一种策略

章节片段财务支持无竞争利益声明：HLY Chan 是 Aligos、Glaxo-Smith-Kline、Roche、Vaccitech、Virion Therapeutics 的顾问；Echossens、Gilead、Roche 的发言人；以及 Aligos、Arbutus、Precision BioSciences、Roche、Vaccitech、Zhimeng Therapeutics 的数据管理委员会成员。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.